Zomedica Provides Product Development Update
ZM-017: Circulating tumor cell assay platform for dogs
As previously disclosed, Zomedica has partnered with
ZM-020: Point-of-care pathogen detection platform for fecal and urine specimens
As previously announced, Zomedica has partnered with
The company expects to begin marketing of ZM-020 in the second half of 2018.
In the longer term, Zomedica also intends to develop additional applications for this technology, including further development of the pathogen detection library for urine and fecal analysis, as well as for respiratory and dermatological analysis. Targeted pathogens may include bacteria, antibiotic resistant bacteria, viruses and fungi.
ZM-007 and ZM-012: Metronidazole for acute diarrhea in dogs
ZM-012 is the Company’s tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs, currently only available as a human generic. ZM-007 is a complementary oral suspension of metronidazole targeting the treatment of acute diarrhea in small dog breeds and puppies under nine pounds or four kilograms, currently only available via compounding pharmacies.
The Company previously designated ZM-012 as its lead therapeutic drug candidate and ZM-007 as a follow-on candidate as a bioequivalent. As previously disclosed, the Company expected to commence a pivotal safety study of ZM-012 in the first half of 2018, which it expected to complete in the second half of 2018. The Company held a pre-submission meeting for metronidazole with the U.S. Food and
ZM-006: Transdermal formulation of methimazole
ZM-006 is a transdermal gel formulation of methimazole targeting hyperthyroidism in cats. The Company previously disclosed that it expected pilot testing of ZM-006 to be completed in the first half of 2018 and, assuming that such pilot testing was successful, to commence and complete a pivotal safety study of ZM-006 in the second half of 2018. In an effort to improve dosing requirements, the Company has decided to continue its pilot testing of ZM-006, which it now expects to complete in the second half of 2018. Assuming that such pilot testing is successful, the Company also intends to commence a pivotal safety study of ZM-006 in the second half of 2018.
ZM-011: Transdermal fluoxetine for feline behavioral disorders
ZM-011 is a transdermal formulation of fluoxetine, most commonly known as Prozac®, which is intended to treat behavioral disorders in cats (e.g., inappropriate urination). Consistent with the Company’s earlier guidance, the Company expects to complete pilot testing of ZM-011 in the second half of 2018.
- Email Alerts: http://investors.zomedica.com
- LinkedIn: https://www.linkedin.com/company/zomedica
- Twitter: https://twitter.com/zomedica
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.
Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the likelihood and timing of regulatory approvals, availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product, intellectual property protection and the other risk factors disclosed in our filings with the
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contacts
Shameze Rampertab, CPA, CA